Trade Lyra Therapeutics, Inc. - LYRA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 5.18 |
| Open | 5.19 |
| 1-Year Change | 159.5% |
| Day's Range | 5.12 - 5.3 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 23, 2024 | 5.18 | 0.00 | 0.00% | 5.18 | 5.35 | 5.13 |
| Apr 22, 2024 | 5.17 | 0.06 | 1.17% | 5.11 | 5.24 | 5.05 |
| Apr 19, 2024 | 5.13 | -0.02 | -0.39% | 5.15 | 5.44 | 5.08 |
| Apr 18, 2024 | 5.34 | -0.04 | -0.74% | 5.38 | 5.47 | 5.18 |
| Apr 17, 2024 | 5.37 | 0.09 | 1.70% | 5.28 | 5.72 | 5.22 |
| Apr 16, 2024 | 5.37 | 0.23 | 4.47% | 5.14 | 5.44 | 5.13 |
| Apr 15, 2024 | 5.23 | -0.03 | -0.57% | 5.26 | 5.35 | 5.16 |
| Apr 12, 2024 | 5.26 | 0.03 | 0.57% | 5.23 | 5.51 | 5.12 |
| Apr 11, 2024 | 5.42 | 0.17 | 3.24% | 5.25 | 5.45 | 5.23 |
| Apr 10, 2024 | 5.22 | 0.25 | 5.03% | 4.97 | 5.25 | 4.91 |
| Apr 9, 2024 | 5.20 | 0.17 | 3.38% | 5.03 | 5.28 | 4.95 |
| Apr 8, 2024 | 5.06 | 0.06 | 1.20% | 5.00 | 5.17 | 4.98 |
| Apr 5, 2024 | 5.00 | -0.26 | -4.94% | 5.26 | 5.36 | 5.00 |
| Apr 4, 2024 | 5.26 | -0.17 | -3.13% | 5.43 | 5.62 | 5.26 |
| Apr 3, 2024 | 5.42 | -0.27 | -4.75% | 5.69 | 5.73 | 5.41 |
| Apr 2, 2024 | 5.57 | -0.56 | -9.14% | 6.13 | 6.13 | 5.57 |
| Apr 1, 2024 | 6.20 | -0.04 | -0.64% | 6.24 | 6.33 | 5.62 |
| Mar 28, 2024 | 6.19 | -0.29 | -4.48% | 6.48 | 6.60 | 6.17 |
| Mar 27, 2024 | 6.50 | 0.37 | 6.04% | 6.13 | 6.72 | 6.13 |
| Mar 26, 2024 | 6.11 | -0.05 | -0.81% | 6.16 | 6.40 | 6.02 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Lyra Therapeutics, Inc. Company profile
About Lyra Therapeutics Inc
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on development and commercialization of novel drug and delivery solutions for the treatment of patients with ear, nose, and throat (ENT) diseases. Its technology platform, XTreo, is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, are bioresorbable polymeric matrices administered in a non-invasive, in-office procedure to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). LYR-210 is an anti-inflammatory implantable drug matrix based on its XTreo platform that is designed to elute mometasone furoate (MF) to the inflamed mucosal tissue for up to six months in surgically naive CRS patients. LYR-220 is an investigative therapy for CRS patients with and without nasal polyps.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Lyra Therapeutics Inc revenues increased from $0K to $285K. Net loss applicable to common stockholders increased 96% to $43.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase from $12.3M to $29.2M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
480 Arsenal Way
WATERTOWN
MASSACHUSETTS 02472
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com